ArticleThe oncologist2022

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.

Mor Moskovitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.